Skip to main content

Table 3 Physiologic outcomes by thiamine supplementation over time

From: Supplemental thiamine for the treatment of acute heart failure syndrome: a randomized controlled trial

Measure

Baseline

Day 1

Day 2

p-value (model)

Control

Treatment

Control

Treatment

Control

Treatment

 

VAS-1st Position (mm)

 Unadjusted (n = 116)*

31 (24–38)

26 (19–33)

17 (12–22)

22 (16–28)

17 (10–24)

21 (15–27)

0.015

 Adjusted (n = 104)**a, b

31 (28–33)

28 (25–30)

16 (11–21)

24 (20–29)

15 (8–22)

26 (19–32)

0.020

VAS-2nd Position (mm)

 Unadjusted (n = 103)*

32 (24–40)

25 (18–32)

19 (13–25)

19 (14–25)

16 (9–23)

18 (13–23)

0.132

 Adjusted (n = 83)** b, c

30 (27–34)

27 (24–29)

17 (12–22)

21 (17–24)

11 (5–18)

20 (15–25)

0.093

VAS-PDA (mm)

 Unadjusted (n = 116)*

103 (78–128)

80 (59–101)

78 (54–102)

59 (40–78)

60 (34–85)

64 (42–85)

0.159

 Adjusted (n = 97)** a, c

85 (76–95)

78 (69–87)

64 (42–86)

61 (47–74)

45 (20–70)

63 (44–82)

0.226

PEFR (L/min)

 Unadjusted (n = 115)*

203 (180–226)

173 (152–194)

206 (183–229)

163 (141–184)

206 (183–230)

167 (146–189)

0.237

 Adjusted (n = 103)** b, d

188 (178–197)

183 (174–192)

193 (184–202)

172 (163–181)

195 (184–205)

178 (168–188)

0.124

NT-proBNP (ng/ml)

 Unadjusted (n = 113)*

0.42 (0.32–0.52)

0.52 (0.35–0.68)

0.45 (0.30–0.61)

0.41 (0.28–0.54)

0.27 (0.21–0.33)

0.37 (0.26–0.48)

0.223

 Adjusted (n = 100)** c

0.46 (0.42–0.50)

0.48 (0.42–0.54)

0.42 (0.34–0.51)

0.34 (0.27–0.41)

0.31 (0.24–0.38)

0.32 (0.24–0.41)

0.209

FFA (mEq/ml)

 Unadjusted (n = 114)*

0.46 (0.38–0.54)

0.47 (0.39–0.56)

0.68 (0.62–0.74)

0.65 (0.59–0.71)

0.62 (0.55–0.68)

0.71 (0.64–0.78)

0.086

 Adjusted (n = 102)** a, b

0.46 (0.41–0.50)

0.45 (0.41–0.50)

0.69 (0.62–0.75)

0.63 (0.56–0.69)

0.62 (0.54–0.69)

0.68 (0.61–0.75)

0.087

Glucose (mg/dl)

 Unadjusted (n = 117)*

166 (146–186)

155 (135–175)

121 (110–132)

112 (102–121)

118 (110–126)

117 (107–126)

0.491

 Adjusted (n = 113)**

161 (150–173)

157 (145–169)

120 (109–130)

113 (99–126)

117 (109–126)

119 (108–131)

0.515

  1. Values are means with 95%CI. P-values are from a test of the treatment*time interaction term in the mixed model
  2. *Includes design variables: site, diabetes medication (self-report) and NT-proBNP quartile
  3. **Additional adjustments for: baseline values of the outcome, thiamine, BMIa, LVEF> = 50% b, PEFR c, systolic BP d